Salarius Pharmaceuticals will rebrand as Decoy Therapeutics in early January 2026, reflecting a strategic pivot to a platform-driven biotechnology company focused on peptide-conjugate therapeutics targeting viral diseases and oncology.

Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.

Salarius Pharmaceuticals has regained compliance with Nasdaq's Minimum Bid Price Requirement and announced a planned merger with Decoy Therapeutics, a preclinical biopharmaceutical company focused on peptide conjugate therapeutics.

Salarius Pharmaceuticals announced two animal studies supporting the potential of its drug seclidemstat in inhibiting LSD1, a target in cancer treatment. The company is progressing a clinical study at MD Anderson Cancer Center and planning a merger with Decoy Therapeutics.

The liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies, including immunotherapies and targeted treatments. The pipeline features 15+ companies and 20+ therapies in various stages of development.